Investigational Drug Information for Almorexant
✉ Email this page to a colleague
What is the development status for investigational drug Almorexant?
Almorexant is an investigational drug.
There have been 7 clinical trials for Almorexant.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2008.
The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Psychomotor Agitation, and Syndrome. The leading clinical trial sponsors are Midnight Pharma, LLC, Diego García-Borreguero, MD, PhD, and Rocío Prieto Pérez.
Summary for Almorexant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 123 |
| WIPO Patent Applications | 64 |
| Japanese Patent Applications | 44 |
| Clinical Trial Progress | Phase 3 (2008-03-01) |
| Vendors | 52 |
Recent Clinical Trials for Almorexant
| Title | Sponsor | Phase |
|---|---|---|
| Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant | Diego Garcia-Borreguero, Paseo de la Habana 151, Madrid 28036, SPAIN | Phase 2 |
| Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant | Sleep Research Institute (Paseo de la Habana 151, Madrid 28036, SPAIN) | Phase 2 |
| Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant | Diego García-Borreguero, MD, PhD | Phase 2 |
Clinical Trial Summary for Almorexant
Top disease conditions for Almorexant
Top clinical trial sponsors for Almorexant
US Patents for Almorexant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
